Marksans Pharma Expands European Footprint with €7.5 Million Strategic Acquisition

Marksans Pharma Ltd. ($MARKSANS) has taken another step in its global expansion strategy by signing a definitive agreement to acquire 100% of the share capital of Netherlands-based QliniQ BV for €7.5 million. The acquisition is expected to strengthen Marksans Pharma’s presence in regulated European markets by providing direct sales, marketing and distribution capabilities across the European Union. QliniQ has built a niche portfolio of pharmaceutical products and medical devices focused on women's health, dermatology and respiratory care, while also maintaining strong relationships with wholesalers, pharmacies, hospitals and insurer-led tender channels in the Netherlands. For the year ended December 2025, QliniQ reported revenue of €9.35 million and a net profit of €1.01 million. The company has demonstrated strong growth, delivering a revenue CAGR of nearly 41% between FY23 and FY25, while maintaining a debt-free balance sheet. The acquisition gives Marksans Pharma direct access to the Dutch market and a stronger platform to commercialize both its existing and future product portfolio across Europe. The transaction reflects the company's continued focus on expanding its international footprint, improving market access and creating long-term growth opportunities in high-value regulated pharmaceutical markets. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.